RMD

Resmed Inc

Sep 17 • 04:00PM ET

271.71

-0.89 -0.33 %

Healthcare • Medical Instruments & Supplies • USA • NYSE

Peers: EW BAX BDX ZBH VNT IART TFX COO HSIC XRAY

| Held by: VTI VOO VO SPY VUG IVV VOT XLV VIG IHI

Index	S&P 500	P/E	28.58	EPS (ttm)	9.51	Insider Own	0.63%	Shs Outstand	146.39M	Perf Week	0.46%
Market Cap	39.78B	Forward P/E	22.54	EPS next Y	12.05	Insider Trans	-7.55%	Shs Float	145.50M	Perf Month	-5.04%
Enterprise Value	39.41B	PEG	2.57	EPS next Q	2.52	Inst Own	65.43%	Short Float	5.85%	Perf Quarter	8.64%
Income	1.40B	P/S	7.73	EPS this Y	14.39%	Inst Trans	-1.51%	Short Ratio	8.57	Perf Half Y	23.36%
Sales	5.15B	P/B	6.66	EPS next Y	10.34%	ROA	18.62%	Short Interest	8.51M	Perf YTD	18.81%
Book/sh	40.77	P/C	32.54	EPS next 5Y	11.14%	ROE	25.86%	52W High	293.81 -7.52%	Perf Year	9.15%
Cash/sh	8.35	P/FCF	23.94	EPS past 3/5Y	21.50% 17.37%	ROIC	20.66%	52W Low	199.92 35.91%	Perf 3Y	14.16%
Dividend Est.	2.48 (0.91%)	EV/EBITDA	20.49	Sales past 3/5Y	12.88% 11.72%	Gross Margin	58.48%	Volatility	1.57% 1.89%	Perf 5Y	57.92%
Dividend TTM	2.19 (0.81%)	EV/Sales	7.66	EPS Y/Y TTM	37.48%	Oper. Margin	32.79%	ATR (14)	5.52	Perf 10Y	439.00%
Dividend Ex-Date	Aug 14, 2025	Quick Ratio	2.53	Sales Y/Y TTM	9.84%	Profit Margin	27.22%	RSI (14)	44.71	Recom	1.93
Dividend Gr. 3/5Y	8.06% 6.33%	Current Ratio	3.44	EPS Q/Q	30.37%	SMA20	-2.16%	Beta	0.84	Target Price	301.29
Payout	22.30%	Debt/Eq	0.14	Sales Q/Q	10.20%	SMA50	-1.17%	Rel Volume	0.84	Prev Close	272.60
Employees	10600	LT Debt/Eq	0.14	Earnings	Jul 31 AMC	SMA200	10.16%	Avg Volume	992.95K	Price	271.71
IPO	Jun 02, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% 0.00%	Trades		Volume	847,461	Change	-0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Upgrade	CLSA	Hold → Outperform
Jul-15-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$294
Mar-19-25	Initiated	Morgan Stanley	Overweight	$280
Mar-19-25	Initiated	Morgan Stanley	Overweight
Jan-16-25	Initiated	Goldman	Buy
Jan-10-25	Initiated	Piper Sandler	Neutral	$252
Dec-13-24	Initiated	Stifel	Hold	$250
Sep-24-24	Initiated	Robert W. Baird	Outperform	$280
Sep-18-24	Downgrade	Wolfe Research	Peer Perform → Underperform	$180
Sep-04-24	Downgrade	Needham	Buy → Hold
Jun-25-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-24-24	Downgrade	Citigroup	Buy → Neutral
Feb-06-24	Resumed	KeyBanc Capital Markets	Overweight	$227
Oct-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$180 → $169
Oct-12-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$273 → $202
Oct-09-23	Upgrade	JP Morgan	Neutral → Overweight	$210 → $170
Sep-29-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-06-23	Upgrade	Needham	Hold → Buy	$180
Sep-05-23	Downgrade	UBS	Buy → Neutral	$265 → $170
Aug-01-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$262 → $284

Show Previous Ratings

Sep-16-25 04:05PM	Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025 (GlobeNewswire)
Sep-15-25 02:07AM	How Is ResMed's Stock Performance Compared to Other Healthcare Stocks? (Barchart)
Sep-12-25 09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
Sep-11-25 11:32PM	Q2 Earnings Outperformers: ResMed (NYSE:RMD) And The Rest Of The Patient Monitoring Stocks (StockStory)
11:12AM	ResMed Inc. (RMD) Launches Global Sleep Institute at World Sleep Congress (Insider Monkey)
06:00PM	Loading…
Sep-10-25 06:00PM	ResMed, Insulet, Lantheus, Inspire Medical Systems, and Evolent Health Shares Plummet, What You Need To Know (StockStory)
Sep-03-25 04:15PM	Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority (GlobeNewswire)
08:51AM	Is it Worth Retaining ResMed Stock in Your Portfolio Now? (Zacks)
Aug-28-25 12:01AM	3 Reasons Investors Watch ResMed (RMD) (StockStory)
Aug-27-25 09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
09:00AM	Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds (GlobeNewswire)
Aug-26-25 08:57AM	Is Wall Street Bullish or Bearish on ResMed Stock? (Barchart)
Aug-21-25 02:03PM	Edwards Lifesciences Stock Pumps Up Its Relative Strength Rating (Investor's Business Daily)
09:00AM	Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs (GlobeNewswire)
Aug-20-25 12:33AM	1 Healthcare Stock Worth Investigating and 2 Facing Challenges (StockStory)
04:15PM	Loading…
Aug-18-25 04:15PM	Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio (GlobeNewswire)
Aug-15-25 10:10AM	Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea (Zacks)
Aug-13-25 09:50AM	Why ResMed (RMD) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-12-25 11:36PM	The Top 5 Analyst Questions From ResMed's Q2 Earnings Call (StockStory)
11:20PM	RMD Q2 Deep Dive: Margin Expansion and Product Innovation Drive Outperformance (StockStory)
Aug-11-25 12:30PM	[Latest] Global High Flow Nasal Cannula Market Size/Share Worth USD 5.9 Billion by 2034 at a 5.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
08:30AM	Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago (Zacks)
Aug-08-25 01:17PM	The Stock Market Gains Despite Noisy Week. Call It Complacency-or the Right Thing to Do. (Barrons.com)
Aug-04-25 04:04AM	Ventilators Company Evaluation Report 2025 - ResMed, Getinge, and Philips Lead the Ventilator Market Through Innovation, Strong Global Presence, and Strategic Use of Technology and Partnerships (GlobeNewswire)
Aug-01-25 01:00PM	Experity Appoints Bobby Ghoshal as President and Chief Operating Officer (PR Newswire)
12:25PM	ResMed (RMD) Stock Is Up, What You Need To Know (StockStory)
10:24AM	Analyst Report: ResMed Inc. (Morningstar Research)
07:51AM	Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb (Zacks)
03:34AM	ResMed Inc (RMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions (GuruFocus.com)
06:00PM	Loading…
Jul-31-25 06:00PM	Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings (Zacks)
05:20PM	ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
05:07PM	ResMed (NYSE:RMD) Surprises With Q2 Sales (StockStory)
04:19PM	ResMed: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025 (GlobeNewswire)
Jul-30-25 08:50AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
06:08AM	Spot Outliers Like ResMed Early with Money Flows (FX Empire)
Jul-29-25 11:08PM	ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
10:00AM	Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline (Zacks)
Jul-24-25 12:10PM	Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:49AM	Labcorp Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market (Zacks)
10:00AM	ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:30AM	If You Invested $1000 in ResMed a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
08:04AM	Here's What to Expect From ResMed's Next Earnings Report (Barchart)
Jul-23-25 11:59AM	Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up (Zacks)
09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:15AM	ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jul-22-25 08:39AM	Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises (Zacks)
Jul-18-25 10:22AM	Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data (Zacks)
Jul-17-25 01:00AM	This Pick Withstood the GLP-1 Challenge. Stick With the Stock. (Barrons.com)
Jul-16-25 09:40AM	Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-15-25 12:04AM	2 Reasons to Watch RMD and 1 to Stay Cautious (StockStory)
Jul-09-25 02:33PM	Semler Scientific Stock Gets Relative Strength Rating Upgrade (Investor's Business Daily)
12:35AM	2 S&P 500 Stocks with Promising Prospects and 1 to Steer Clear Of (StockStory)
Jul-01-25 04:05PM	Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 (GlobeNewswire)
Jun-30-25 09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jun-26-25 04:40AM	Zacks.com featured highlights Sprouts Farmers Market, Adobe, GE Aerospace and ResMed (Zacks)
Jun-25-25 12:00PM	All You Need to Know About ResMed (RMD) Rating Upgrade to Buy (Zacks)
08:57AM	Scoop Up These 4 GARP Stocks to Receive Handsome Returns (Zacks)
Jun-24-25 07:33PM	Analyst Report: ResMed Inc. (Morningstar Research)
Jun-18-25 08:27AM	ResMed's Q1 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Jun-10-25 07:00PM	ResMed: A Mixed Bag for Investors Amid Rising Competition (Motley Fool)
Jun-06-25 11:31AM	Phibro (PAHC) Up 7.4% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 09:45AM	ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Jun-02-25 12:35AM	2 Healthcare Stocks to Keep an Eye On and 1 to Turn Down (StockStory)
May-30-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-23-25 11:30AM	ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
06:52AM	Is it Worth Retaining ResMed Stock in Your Portfolio Now? (Zacks)
May-21-25 10:10AM	Morgan Stanley sees modest earnings impact to ResMed from Apnimed (TipRanks)
May-19-25 09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
May-18-25 04:20AM	3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term (Motley Fool)
May-15-25 09:00AM	Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 (GlobeNewswire)
May-06-25 12:31AM	3 Profitable Stocks to Consider Right Now (StockStory)
May-03-25 10:39PM	Top 50 High-Quality Dividend Stocks For May 2025 (Seeking Alpha)
01:26AM	Dividend Champion, Contender, And Challenger Highlights: Week Of May 4 (Seeking Alpha)
May-02-25 11:21AM	Top 15 High-Growth Dividend Stocks To Consider For May 2025 (Seeking Alpha)
06:50AM	Resmed acquires independent diagnostic testing facility VirtuOx (Medical Device Network)
06:00AM	Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility (MedTech Dive)
May-01-25 09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
09:00AM	Resmed Acquires VirtuOx (GlobeNewswire)
Apr-30-25 04:03PM	Resmed Inc (RMD): Jim Cramer Says "Remarkable Stock" - Did GLP-1 Drugs Just Hand It a Lifeline? (Insider Monkey)
Apr-26-25 06:09PM	RMD Q1 Earnings Call: Margin Expansion and Demand Generation Initiatives Define Quarter (StockStory)
Apr-25-25 12:00PM	MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up (Zacks)
09:50AM	ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
07:10AM	Buy These 5 Low-Leverage Stocks to Counter Market Volatility (Zacks)
Apr-24-25 08:21AM	Q3 2025 Resmed Inc Earnings Call (Thomson Reuters StreetEvents) +10.10%
08:07AM	Analyst Report: ResMed Inc. (Morningstar Research)
07:24AM	ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market (Zacks)
05:12AM	ResMed: Cornering The Market In Sleep Solutions (Seeking Alpha)
03:06AM	ResMed Inc (RMD) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Apr-23-25 07:16PM	ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript (Seeking Alpha)
06:00PM	Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings (Zacks)
05:15PM	ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates (Zacks)
04:23PM	ResMed's (NYSE:RMD) Q1 Earnings Results: Revenue In Line With Expectations (StockStory)
04:19PM	ResMed: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 (GlobeNewswire)
03:40AM	Magnificent 7 Earnings Out This Week Will Shed Light On Big Tech's Tariff Concerns (Seeking Alpha)
Apr-22-25 08:02AM	Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow (StockStory)
Apr-21-25 05:00PM	Resmed Names Salli Schwartz as Chief Investor Relations Officer (GlobeNewswire)

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farrell Michael J.	Chief Executive Officer	Sep 08 '25	Option Exercise	101.64	8,009	814,035	475,801	Sep 09 04:10 PM
Farrell Michael J.	Chief Executive Officer	Sep 08 '25	Sale	278.14	8,009	2,227,590	467,792	Sep 09 04:10 PM
Farrell Michael J.	Officer	Sep 08 '25	Proposed Sale	278.14	8,009	2,227,591		Sep 08 04:22 PM
Sandercock Brett	Chief Financial Officer	Sep 02 '25	Option Exercise	101.64	2,000	203,280	90,745	Sep 03 05:39 PM
Sandercock Brett	Chief Financial Officer	Sep 02 '25	Sale	270.77	3,000	812,310	87,745	Sep 03 05:39 PM
Sandercock Brett	Officer	Sep 02 '25	Proposed Sale	270.77	3,000	812,310		Sep 02 12:02 PM
Hernandez John	Director	Aug 18 '25	Option Exercise	148.90	2,575	383,418	6,620	Aug 19 01:10 PM
Hernandez John	Director	Aug 18 '25	Sale	287.10	2,575	739,289	4,045	Aug 19 01:10 PM
Hernandez John	Director	Aug 18 '25	Proposed Sale	287.10	2,575	739,289		Aug 18 03:11 PM
Farrell Michael J.	Chief Executive Officer	Aug 07 '25	Option Exercise	101.64	8,009	814,035	463,512	Aug 11 10:45 AM
Farrell Michael J.	Chief Executive Officer	Aug 07 '25	Sale	279.48	8,009	2,238,379	455,503	Aug 11 10:45 AM
Farrell Michael J.	Officer	Aug 07 '25	Proposed Sale	282.83	8,009	2,265,185		Aug 07 11:20 AM
Sandercock Brett	Chief Financial Officer	Aug 01 '25	Option Exercise	101.64	2,000	203,280	86,283	Aug 05 12:16 PM
Sandercock Brett	Chief Financial Officer	Aug 01 '25	Sale	281.90	3,000	845,700	83,283	Aug 05 12:16 PM
Rider Michael J	Global General Counsel	Aug 01 '25	Sale	281.90	50	14,095	8,486	Aug 04 07:55 PM
Rider Michael J	Officer	Aug 01 '25	Proposed Sale	281.90	50	14,095		Aug 01 11:52 AM
Sandercock Brett	Officer	Aug 01 '25	Proposed Sale	281.90	3,000	845,700		Aug 01 11:07 AM
Farrell Michael J.	Chief Executive Officer	Jul 07 '25	Option Exercise	101.64	8,009	814,035	463,512	Jul 09 08:37 AM
Farrell Michael J.	Chief Executive Officer	Jul 07 '25	Sale	256.72	8,009	2,056,076	455,503	Jul 09 08:37 AM
Farrell Michael J.	Officer	Jul 07 '25	Proposed Sale	256.72	8,009	2,056,076		Jul 07 05:21 PM
FARRELL PETER C	Director	Jul 02 '25	Sale	255.49	945	241,438	68,273	Jul 03 12:01 PM
Sandercock Brett	Chief Financial Officer	Jul 01 '25	Option Exercise	101.64	2,883	293,028	88,166	Jul 02 05:53 PM
Sandercock Brett	Chief Financial Officer	Jul 01 '25	Sale	256.99	3,883	997,892	84,283	Jul 02 05:53 PM
FARRELL PETER C	Director	Jul 02 '25	Proposed Sale	264.55	945	250,000		Jul 02 04:15 PM
Rider Michael J	Global General Counsel	Jul 01 '25	Sale	256.99	66	16,961	8,536	Jul 02 03:57 PM
Rider Michael J	Officer	Jul 01 '25	Proposed Sale	256.99	66	16,961		Jul 01 12:40 PM
Sandercock Brett	Officer	Jul 01 '25	Proposed Sale	256.99	3,883	997,892		Jul 01 10:35 AM
Farrell Michael J.	Chief Executive Officer	Jun 09 '25	Option Exercise	101.64	8,009	814,035	463,512	Jun 10 06:35 PM
Farrell Michael J.	Chief Executive Officer	Jun 09 '25	Sale	251.21	8,009	2,011,910	455,503	Jun 10 06:35 PM
Farrell Michael J.	Officer	Jun 09 '25	Proposed Sale	252.00	8,009	2,018,268		Jun 09 10:26 AM
FARRELL PETER C	Director	Jun 04 '25	Sale	247.32	2,000	494,640	69,218	Jun 06 03:22 PM
FARRELL PETER C	Director	Jun 04 '25	Proposed Sale	250.00	2,000	500,000		Jun 04 07:19 PM
Sandercock Brett	Chief Financial Officer	Jun 02 '25	Sale	243.78	1,000	243,780	85,283	Jun 03 05:59 PM
Rider Michael J	Global General Counsel	Jun 02 '25	Sale	243.78	41	9,995	8,870	Jun 03 01:13 PM
Rider Michael J	Officer	Jun 02 '25	Proposed Sale	243.78	41	9,995		Jun 02 01:42 PM
Sandercock Brett	Officer	Jun 02 '25	Proposed Sale	243.78	1,000	243,780		Jun 02 09:58 AM
Sandercock Brett	Chief Financial Officer	May 22 '25	Sale	244.59	3,644	891,286	86,283	May 27 10:24 AM
Sandercock Brett	Officer	May 22 '25	Proposed Sale	244.59	3,644	891,286		May 22 10:25 AM
De Witte Jan	Director	May 20 '25	Sale	243.47	2,000	486,940	5,806	May 22 10:05 AM
De Witte Jan	Director	May 20 '25	Proposed Sale	243.47	2,000	486,940		May 20 11:25 AM
Farrell Michael J.	Chief Executive Officer	May 07 '25	Option Exercise	101.64	8,009	814,035	463,512	May 09 11:01 AM
Farrell Michael J.	Chief Executive Officer	May 07 '25	Sale	243.23	8,009	1,948,003	455,503	May 09 11:01 AM
FARRELL PETER C	Director	May 07 '25	Sale	242.25	2,000	484,500	71,218	May 08 05:38 PM
FARRELL PETER C	Director	May 07 '25	Proposed Sale	250.00	2,000	500,000		May 07 08:12 PM
Farrell Michael J.	Officer	May 07 '25	Proposed Sale	243.23	8,009	1,948,003		May 07 04:14 PM
Sandercock Brett	Chief Financial Officer	Apr 08 '25	Sale	215.58	1,000	215,580	89,864	Apr 10 06:14 PM
Farrell Michael J.	Chief Executive Officer	Apr 07 '25	Option Exercise	101.64	8,009	814,035	463,482	Apr 09 10:52 AM
Farrell Michael J.	Chief Executive Officer	Apr 07 '25	Sale	209.85	8,009	1,680,699	455,472	Apr 09 10:52 AM
Sandercock Brett	Officer	Apr 08 '25	Proposed Sale	215.58	1,000	215,580		Apr 08 09:43 AM
Farrell Michael J.	Officer	Apr 07 '25	Proposed Sale	209.85	8,009	1,680,699		Apr 07 04:15 PM
FARRELL PETER C	Director	Apr 02 '25	Sale	219.74	2,000	439,480	73,218	Apr 04 12:47 PM
Rider Michael J	Global General Counsel	Apr 01 '25	Sale	222.86	64	14,263	8,846	Apr 03 12:59 PM
FARRELL PETER C	Director	Apr 02 '25	Proposed Sale	222.30	2,000	444,600		Apr 02 05:00 PM
Rider Michael J	Officer	Apr 01 '25	Proposed Sale	222.86	64	14,263		Apr 01 11:08 AM
Sandercock Brett	Chief Financial Officer	Mar 10 '25	Sale	230.36	1,000	230,360	90,864	Mar 11 09:56 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Mar 10 '25	Option Exercise	186.53	9,745	1,817,753	19,470	Mar 11 04:19 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Mar 10 '25	Sale	239.31	9,745	2,332,096	9,725	Mar 11 04:19 PM
Farrell Michael J.	Chief Executive Officer	Mar 07 '25	Option Exercise	101.64	8,009	814,035	463,481	Mar 11 11:04 AM
Farrell Michael J.	Chief Executive Officer	Mar 07 '25	Sale	229.20	8,009	1,835,692	455,472	Mar 11 11:04 AM
Ghoshal Kaushik	Officer	Mar 10 '25	Proposed Sale	239.31	9,745	2,332,097		Mar 10 04:42 PM
Sandercock Brett	Officer	Mar 10 '25	Proposed Sale	230.36	1,000	230,360		Mar 10 09:58 AM
Farrell Michael J.	Officer	Mar 07 '25	Proposed Sale	224.43	8,009	1,797,460		Mar 07 12:12 PM
FARRELL PETER C	Director	Mar 05 '25	Sale	227.71	2,000	455,420	75,218	Mar 06 05:40 PM
FARRELL PETER C	Director	Mar 05 '25	Proposed Sale	250.00	2,000	500,000		Mar 05 07:20 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Mar 03 '25	Option Exercise	182.90	9,113	1,666,780	18,838	Mar 04 05:25 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Mar 03 '25	Sale	235.40	9,113	2,145,186	9,725	Mar 04 05:25 PM
Rider Michael J	Global General Counsel	Mar 03 '25	Sale	234.10	64	14,982	8,910	Mar 04 04:51 PM
Ghoshal Kaushik	Officer	Mar 03 '25	Proposed Sale	235.42	9,113	2,145,408		Mar 03 04:40 PM
Rider Michael J	Officer	Mar 03 '25	Proposed Sale	234.10	64	14,982		Mar 03 10:27 AM
Sandercock Brett	Chief Financial Officer	Feb 10 '25	Sale	238.98	1,000	238,980	91,864	Feb 11 12:55 PM
Farrell Michael J.	Chief Executive Officer	Feb 07 '25	Option Exercise	101.64	8,009	814,035	463,481	Feb 11 12:54 PM
Farrell Michael J.	Chief Executive Officer	Feb 07 '25	Sale	236.77	8,009	1,896,307	455,472	Feb 11 12:54 PM
Sandercock Brett	Officer	Feb 10 '25	Proposed Sale	238.98	1,000	238,980		Feb 10 11:31 AM
Farrell Michael J.	Officer	Feb 07 '25	Proposed Sale	236.77	8,009	1,896,307		Feb 07 04:28 PM
FARRELL PETER C	Director	Feb 05 '25	Proposed Sale	250.00	2,000	500,000		Feb 05 06:57 PM
FARRELL PETER C	Director	Feb 05 '25	Sale	242.11	2,000	484,220	77,218	Feb 05 04:49 PM
Rider Michael J	Global General Counsel	Feb 03 '25	Sale	242.42	64	15,515	8,974	Feb 04 12:18 PM
Rider Michael J	Officer	Feb 03 '25	Proposed Sale	242.42	64	15,515		Feb 03 11:12 AM
Sandercock Brett	Chief Financial Officer	Jan 08 '25	Sale	234.04	1,000	234,040	92,864	Jan 10 04:52 PM
Sandercock Brett	Officer	Jan 08 '25	Proposed Sale	234.04	1,000	234,040		Jan 08 10:32 AM
FARRELL PETER C	Director	Jan 02 '25	Sale	230.99	2,000	461,980	79,218	Jan 03 04:57 PM
Rider Michael J	Global General Counsel	Jan 02 '25	Sale	230.99	75	17,324	9,038	Jan 03 04:52 PM
FARRELL PETER C	Director	Jan 02 '25	Proposed Sale	250.00	2,000	500,000		Jan 02 06:06 PM
Rider Michael J	Officer	Jan 02 '25	Proposed Sale	230.99	75	17,324		Jan 02 11:11 AM
Sandercock Brett	Chief Financial Officer	Dec 09 '24	Sale	244.23	1,000	244,230	93,864	Dec 11 01:17 PM
Sandercock Brett	Officer	Dec 09 '24	Proposed Sale	244.23	1,000	244,230		Dec 09 11:12 AM
FARRELL PETER C	Director	Dec 04 '24	Sale	245.65	2,000	491,300	81,218	Dec 05 06:44 PM
FARRELL PETER C	Director	Dec 04 '24	Proposed Sale	250.00	2,000	500,000		Dec 04 07:57 PM
Rider Michael J	Global General Counsel	Dec 02 '24	Sale	248.91	74	18,419	9,113	Dec 02 06:02 PM
Rider Michael J	Officer	Dec 02 '24	Proposed Sale	248.91	74	18,419		Dec 02 11:11 AM
Farrell Michael J.	Director	Nov 27 '24	Proposed Sale	250.00	2,000	500,000		Nov 27 06:17 PM
Farrell Michael J.	Chief Executive Officer	Nov 27 '24	Sale	249.66	2,000	499,330	0	Nov 27 03:19 PM
Leong Justin	Chief Product Officer	Nov 22 '24	Sale	243.09	6,160	1,497,416	21,718	Nov 25 11:14 AM
Leong Justin	Officer	Nov 22 '24	Proposed Sale	243.09	6,160	1,497,418		Nov 22 04:37 PM
De Witte Jan	Director	Nov 12 '24	Sale	248.81	796	198,053	6,723	Nov 14 11:49 AM
Farrell Michael J.	Chief Executive Officer	Nov 07 '24	Option Exercise	84.98	14,683	1,247,761	478,937	Nov 12 05:37 PM
Farrell Michael J.	Chief Executive Officer	Nov 07 '24	Sale	246.26	14,683	3,615,821	464,254	Nov 12 05:37 PM
Sandercock Brett	Chief Financial Officer	Nov 08 '24	Sale	249.00	1,000	249,000	94,864	Nov 12 04:33 PM
De Witte Jan	Director	Nov 12 '24	Proposed Sale	248.81	796	198,053		Nov 12 11:54 AM
FARRELL PETER C	Director	Nov 06 '24	Sale	248.74	2,000	497,480	83,204	Nov 08 01:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RMD

Resmed Inc

Upgrade your FINVIZ experience